ArticleScientific reports2025
Circulating CHI3L1 autoantibodies serve as a diagnostic biomarker in patients with obstructive sleep apnea.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammation in Obstructive Sleep Apnea: A Global Bibliometric Perspective.Nature and science of sleep · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
While polysomnography (PSG) is the gold standard for diagnosing obstructive sleep apnea (OSA), its limited availability means that many patients remain undiagnosed. This study seeks to evaluate whether CHI3L1-Ab could serve as a diagnostic biomarker for OSA. A total of 366 individuals, including 333 OSA patients and 33 healthy controls, were recruited for this study, all of whom underwent polysomnography. Enzyme-linked immunosorbent assay (ELISA) was used to measure CHI3L1-Ab levels, and clinical factors were analyzed to assess their relationship with CHI3L1-Ab expression. OSA patients exhibited significantly higher CHI3L1-Ab levels compared to healthy controls (P < 0.05), with an area under the curve (AUC) of 0.721. Subgroup analysis revealed the highest AUC of 0.735 (95% CI 0.637-0.832) in patients with severe OSA. Logistic regression analysis, which incorporated age, BMI and CHI3L1-Ab levels, demonstrated strong predictive performance with an AUC of 0.846 (95% CI 0.815-0.942). The corresponding nomogram allowed individualized risk estimation based on these predictors. The combination of CHI3L1-Ab levels, age and BMI demonstrated strong predictive accuracy in distinguishing OSA from healthy individuals. These findings also suggest that elevated CHI3L1-Ab levels could serve as an independent diagnostic biomarker for OSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.